Drug Target Review
OCTOBER 3, 2024
Overcoming traditional antibody generation limitations with recombinant technologies Antibodies remain essential tools in this ever-changing field for preclinical bioanalysis and drug monitoring through ligand-binding assays (LBAs). Adapted from Harth S et al. (8) 8) under a CC BY-NC-ND 4.0. Journal of Molecular Biology.
Alta Sciences
AUGUST 21, 2023
Our solutions include standalone services or integrated programs, providing assay development and top-quality data for toxicokinetic (TK) , pharmacokinetic (PK), and pharmacodynamic (PD) determinations to support your nonclinical and clinical studies. Why Partner With Altasciences for Your Bioanalytical Projects?
Agency IQ
FEBRUARY 2, 2024
The protocol and statistical analysis plan should clearly specify the plans for specimen collection, sample analysis and related clinical outcomes depending on the biomarker assay development and validation strategy.
Expert insights. Personalized for you.
52 
Let's personalize your content